NCT00003048View on ClinicalTrials.gov

Amifostine in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 5, 1997

Primary Completion Date

February 12, 2001

Study Completion Date

February 12, 2001

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Amifostine Trihydrate

Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003048 - Amifostine in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter